Data from Bevacizumab, Atezolizumab, and Acetylsalicylic Acid in Recurrent, Platinum-Resistant Ovarian Cancer: The EORTC 1508-GCG Phase II Study
Susana Banerjee(Royal Marsden NHS Foundation Trust), George Coukos(Ludwig Cancer Research), Judith R. Kroep(Leiden University Medical Center), Eleonora Ghisoni(Centre Hospitalier Universitaire Vaudois), Matteo Morotti(University Hospital of Lausanne), Corneel Coens(European Organisation for Research and Treatment of Cancer), Anita Wolfer(University of Geneva), Apostolos Sarivalasis(Centre Hospitalier Universitaire Vaudois), Petronella B. Ottevanger(Radboud University Nijmegen), Fernanda Herrera(Centre Hospitalier Universitaire Vaudois), Petr Szturz(University of Lausanne), Denarda Dangaj Laniti(Ludwig Cancer Research), Julien Dagher(University of Lausanne), Romuald Le Scodan(Centre Hospitalier privé Saint Grégoire), Lana E. Kandalaft(Clinique de Genolier), Ana Montes(Guy's and St Thomas' NHS Foundation Trust), Margarita Romeo(Institut Català d'Oncologia)
Cited by 0
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k